Serving Overlooked PatientsSM
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.
PRODUCT ANNOUNCEMENT
NOW AVAILABLE

Click for Full Prescribing Information,
including Indication, BOXED WARNING, and Important Safety Information.
PRODUCT ANNOUNCEMENT

Click for Full Prescribing Information, including Indication and Additional Safety Information.
PRODUCT ANNOUNCEMENT
NOW AVAILABLE

Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information.
PRODUCT ANNOUNCEMENT

Click for Full Prescribing Information, including Indication and Additional Safety Information.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
News & Events
Azurity Pharmaceuticals Announces FDA Approval of Aprepitant Injectable Emulsion, Expanding Access to Critical Supportive Oncology Care
WOBURN, MA – June 25, 2026 – Azurity Pharmaceuticals, a global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administration (FDA) has approved Aprepitant Injectable Emulsion, a practical, administration-friendly treatment option aimed at making the patient experience more manageable.
ACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme® and Ferabright™ in Macau
NEW YORK, NY May 21, 2026 — ACA Pharma and Azurity Pharmaceuticals announced that Feraheme® and Ferabright™ have each received regulatory approval in Macau, marking an important step in expanding access to ferumoxytol-based products across key markets in Asia. These approvals reflect the continued collaboration between ACA Pharma and Azurity to advance regulatory pathways and improve patient access throughout Greater China.